{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.90","value":"-3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.78","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.13","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.13","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.97","value":"15.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.76","value":"11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.17","value":"14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 15, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.11","value":"8.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.55","value":"-0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 19, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.28","value":"-13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.14","value":"-3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.40","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Final visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as \"not at all\" and 4 as \"very much.\" The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG000","title":"Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) population: all participants who received at least one dose of study drug; participants who have both baseline and post-baseline values are included in the analysis at each visit","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit","title":"Phase 2: Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"units on a scale"}